|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.12 USD | +0.74% |
|
-11.26% | +61.75% |
| 05-09 | ImmunityBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 05-07 | ImmunityBio Shares Rise After Completion of Drug Substance Manufacturing for Cancer Treatment | MT |
April 22 (Reuters) - The U.S. FDA had approved ImmunityBio's combination therapy to treat a type of bladder cancer, the company said on Monday.
(Reporting by Puyaan Singh; Editing by Sherry Jacob-Phillips)
| 1st Jan change | Capi. | |
|---|---|---|
| +61.75% | 5.5B | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
IMMUNITYBIO, INC. 
